Talphera (R5XA) Stock Overview
A specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
R5XA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Talphera, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.89 |
| 52 Week High | US$1.24 |
| 52 Week Low | US$0.30 |
| Beta | 0.25 |
| 1 Month Change | -16.20% |
| 3 Month Change | 12.80% |
| 1 Year Change | 58.08% |
| 3 Year Change | -58.22% |
| 5 Year Change | -96.01% |
| Change since IPO | -98.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| R5XA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.2% | 0.7% |
| 1Y | 58.1% | 11.3% | 14.2% |
Return vs Industry: R5XA exceeded the German Pharmaceuticals industry which returned 11.3% over the past year.
Return vs Market: R5XA exceeded the German Market which returned 14.2% over the past year.
Price Volatility
| R5XA volatility | |
|---|---|
| R5XA Average Weekly Movement | 13.6% |
| Pharmaceuticals Industry Average Movement | 6.3% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in DE Market | 12.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: R5XA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: R5XA's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 13 | Vince Angotti | talphera.com |
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company’s lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, a nafamostat formulation for direct IV infusion as an investigational product for various indications, such as antiviral, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis, as well as Fedsyra and phenylephrine ready-to-use pre-filled syringe product candidates.
Talphera, Inc. Fundamentals Summary
| R5XA fundamental statistics | |
|---|---|
| Market cap | €45.24m |
| Earnings (TTM) | -€10.61m |
| Revenue (TTM) | €23.84k |
Is R5XA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| R5XA income statement (TTM) | |
|---|---|
| Revenue | US$28.00k |
| Cost of Revenue | US$5.80m |
| Gross Profit | -US$5.77m |
| Other Expenses | US$6.69m |
| Earnings | -US$12.46m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.27 |
| Gross Margin | -20,596.43% |
| Net Profit Margin | -44,503.57% |
| Debt/Equity Ratio | 33.9% |
How did R5XA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/02 12:59 |
| End of Day Share Price | 2025/12/30 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Talphera, Inc. is covered by 15 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| David Buck | B. Riley Securities, Inc. |
| Andrew D'Silva | B. Riley Securities, Inc. |